2011 discharge: European Medicines Agency

This procedure concerns the 'discharge' process, which is the final approval of how the European Medicines Agency (EMA) managed its budget for the 2011 financial year. It is a key part of democratic oversight to ensure that EU funds were spent legally, efficiently, and for their intended purposes.

This affects the administration of the EMA. A positive discharge confirms that the agency's financial management was satisfactory, while a refusal would signal serious irregularities in spending.